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ABSTRACT
Objectives: chronic low back pain 
may result in central sensitization, 
with involvement of different recep-
tors. The aim of this study was to 
evaluate the analgesic action of trans-
dermal (T) ketamine (a NMDA an-
tagonist), clonidine (an α2-agonist), 
fentanyl (an opioid agonist), or their 
combination in chronic low back 
pain. Methods: after the institutio-
nal approval and informed consent 
signature, 54 patients were prospec-
tively  randomized into 6 groups. 
Each patient had two of the T prepa-
rations applied in different arms. The 
effect of either T ketamine (1 mg/h), 
T clonidine (25 μg/h) or T fentanyl 
(25 μg/h), combined with T placebo 
(CloG, KetG and FenG); or the com-
bination of T ketamine and clonidine 
RESUMO 
Objetivos: a dor lombar crônica pode 
resultar em sensibilização central, 
com a participação de diferentes tipos 
de receptores. O objetivo deste estudo 
foi avaliar a ação analgésica por via 
transdérmica (T) do fentanil, ceta-
mina, clonidina ou suas associações 
para o alívio da dor lombar crônica. 
Métodos: após aprovação do Comitê 
de Ética em Pesquisa e assinatura do 
termo de consentimento livre e escla-
recido, 54 pacientes foram avaliados 
de forma prospectiva, aleatória e du-
plamente-encoberta, sendo divididos 
em 6 grupos. Cada paciente recebeu 
duas preparações por via transdérmi-
ca, aplicadas em braços diferentes (T 
cetamina (1 mg/h), T clonidina (25 
μg/h) ou T fentanil (25 μg/h), asso-
ciados a T placebo (CloG, CetG and 
RESUMEN
Objetivos: el dolor lumbar cróni-
co puede resultar en sensibilización 
central, con la participación de dife-
rentes tipos de receptores. El objetivo 
de este estudio fue evaluar la acción 
analgésica por vía transdérmica (T) 
del fentanyl, cetamina, clonidina o 
sus asociaciones en dolor lumbar 
crónico. Métodos: después de la 
aprobación por el Comité de Ética en 
Investigación y Consentimiento, 54 
pacientes fueron evaluados de forma 
prospectiva, aleatoria e duplamente-
ciego siendo divididos en seis grupos. 
Cada paciente recibió dos prepara-
ciones por vía transdérmica, aplica-
das en brazos diferentes (T cetamina 
(1 mg/h), T clonidina (25 μg/h) o T 
fentanyl (25 μg/h), asociados a T 
placebo (CloG, CetG y FenG); o la 
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(Ket-CloG), T fentanyl and ketamine 
(Fen-KetG), or T fentanyl and clo-
nidine (Fen-CloG) was searched for 
pain and adverse effects. Pain was 
evaluated by: 1) VAS pain scores, and 
2) noradrenaline plasma levels at 0-h 
(just prior to T application), 3- and 6-h 
after the T application of two medica-
tions, by HPLC. Results: clinically, 
the pain VAS score at 6-h was smaller 
in comparison to the 0-h in all groups 
(p<0.02), and lower when compared 
to the Fen-CloG and Fen-KetG at the 
6-h in relation to the administration 
of each correspondent T drug alone 
(p<0.05). The laboratorial data reve-
aled that administration of T fentanyl 
alone (FenG) resulted in plasma no-
radrenaline decrease at 6-h (p<0.01), 
while the association of T fentanyl 
with clonidine resulted in plasma no-
radrenaline decrease at 3- and 6-h as 
compared to the others (p<0.01). The 
combination of both T ketamine and 
clonidine (Ket-CloG) did not result in 
a better analgesic profile and resulted 
in excessive sedation during the eva-
luation (p<0.02). Conclusions: all 
the studied drugs resulted in clinical 
analgesia (VAS) at 6-h. However, T 
fentanyl analgesia was corroborated 
by lower plasma noradrenaline levels 
at 6-h when applied alone or at 3-h 
when combined with T clonidine.
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Analgesics/administration 
& dosage; Clonidine/
administration & dosage; 
Ketamine/administration 
& dosage; Fentanyl/
administration & dosage; 
Administration, cutaneous; 
Low back pain/drug therapy 
FenG); ou a associação de T cetamina 
e clonidina (Cet-CloG), T fentanil e 
cetamina (Fen-CetG), ou T fentanil 
e clonidina (Fen-CloG). A analgesia 
e a incidência de efeitos adversos fo-
ram avaliadas.  A analgesia foi ava-
liada com: 1) VAS-cm, e 2) níveis 
plasmáticos de noradrenalina às 0-h 
(antes da aplicação T), 3- e 6-h após 
a aplicação T, com HPLC. Resulta-
dos: clinicamente, os valores de VAS 
as 6-h foram menores comparados ao 
tempo de 0-h para todos os grupos 
(p<0,02), e menores para o Fen-CloG 
e Fen-CetG às 6-h em relação à ad-
ministração de cada droga T isolada 
(p<0,05). A administração de fentanil 
T (FenG) resultou em diminuição dos 
níveis de noradrenalina plasmática às 
6-h (p<0,01), enquanto a associação 
de fentanil T com clonidina T resul-
tou em diminuição de noradrenalina 
plasmática às 3-h e 6-h em compa-
ração aos demais grupos (p<0.01). A 
combinação de cetamina e clonidina 
(Cet-CloG) não ofereceu melhor per-
fil analgésico e resultou em sedação 
excessiva (p<0,02). Conclusões: to-
dos os grupos apresentaram melhora 
clínica (VAS) da dor às 6-h. Entretan-
to, somente quem recebeu fentanil T 
apresentou níveis plasmáticos de no-
radrenalina mais baixos às 6-h (quan-
do combinado com placebo) e às 3-h 
quando associado à clonidina T. 
DESCRITORES: Analgesia epidural; 
Analgésicos/administração 
& dosagem; Clonidina/
administração & dosagem; 
Ketamina/administração 
& dosagem; Fentanila/
administração & dosagem; 
Administração cutânea; Dor 
lombar/quimioterapia
asociación de T cetamina y clonidi-
na (Cet-CloG), T fentanyl y cetamina 
(Fen-CetG), o T fentanyl  y clonidi-
na (fen-CloG). La analgesia y la in-
cidencia de efectos adversos fueron 
evaluadas. La analgesia fue evaluada 
con: 1) VAS-cm, y 2) niveles plasmá-
ticos de noradrenalina a las 0 hora 
(antes de la aplicación T), tres y seis 
horas después de la aplicación T, con 
HPLC. Resultados: clínicamente los 
valores de VAS a las seis horas fueron 
menores comparados a 0 hora para 
todos los grupos (p<0,02), y meno-
res para el Fen-CloG y Fen-CetG a 
las seis horas después de la admi-
nistración de cada droga T aislada 
(p<0,05). La administración de fen-
tanyl T (Feng) resultó en disminución 
de los niveles de noradrenalina plas-
mática a las seis horas (p<0,01). La 
combinación de cetamina y clonidina 
(Cet-CloG) no ofreció mejor perfil 
analgésico y resultó en sedación ex-
cesiva (p<0,02). Conclusiones: todos 
los grupos presentaron mejoría clíni-
ca (VAS) del dolor a las seis horas. 
Sin embargo, solamente quien recibió 
fentanyl T presentó menores niveles 
plasmáticos de noradrenalina a las 
seis horas (cuando combinado con 
placebo) y a las tres horas cuando 
asociado con clonidina T.
DESCRIPTORES: Analgesia 
epidural; Analgésicos/
administración & dosificación; 
Clonidina/administración 
& dosificación; Cetamina/
administración & dosificación; 
Fentanilo/administración & 
dosificación; Administración 
cutánea; Dolor de la región 
lumbar/quimioterapia
INTRODUCTION
Persistent nociception following low back pain may lead 
to transcriptional and translational changes in the spinal 
cord and brain, resulting in central sensitization and pain. 
It involves different spinal processes, and the participa-
tion of N-methyl-D-aspartate (NMDA)1, α2-adrenergic2 
and opioid receptors3 may play a role. The purpose of this 
paper was to evaluate the analgesic action of transdermal 
(T) ketamine (a NMDA antagonist), clonidine (an α2-
agonist), fentanyl (an opioid agonist), or their combina-
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Transdermal system for controlled liberation 
of the active drug
CloG Placebo + clonidine 25 μg/h
KetG Placebo + ketamine 1μg/h
FenG Placebo + fentanyl 25 μg/h
Ket-CloG Ketamine 1μg/h+ clonidine 25μg/h
Fen-KetG Fentanyl 25 μg/h+ ketamine 1μg/h
Fen-CloG Fentanyl 25 μg/h+ clonidine 25 μg/h
TABLE 1 - Groups
Clo: clonidine; Ket: ketamine; Fen: fentanyl; G: group
tion in chronic non-radicular low back pain. The study was 
conducted and limited to duration of assessment because 
of our interest in defining the best drugs association, in or-
der to direct us for future and long-time evaluation studies. 
Plasma measurement of noradrenaline, a predictive stress 
neurotransmitter4, was carried out to corroborate any anal-
gesic effect from the T systems applied.
METHODS
After the Ethics Committee approval and written informed 
consent signature, 54 ASA status II patients suffering from 
chronic low back pain were computer-randomized to one 
of six groups and prospectively evaluated using a placebo-
controlled double-blind design to examine analgesia and 
adverse effects (n=9). All patients located for the study 
design presented complaints of chronic intractable non-
radicular low back pain secondary to disc degeneration, 
degenerative arthritis in the intervertebral joints and os-
teophytes, were under physiotherapy treatment and had 
been previously submitted to a sequence of three weekly 
caudal blocks with 10 mg of depot-dexamethasone com-
bined with 30 μg of clonidine and 40 mg of lidocaine 
(with added saline to a 10-ml final volume) as part of our 
routine protocol at the Pain Clinic, two months before the 
study day. All patients were taken 25-50 mg amitriptyline 
at bedtime and 20 mg omeprazol in the morning. Oral 100 
mg ketoprofen tablet was prescribed as rescue analgesic 
up to twice daily. However, from the day before the study, 
no rescue analgesic was allowed, in order to evaluate the 
analgesic effect of the proposed T drugs.
The concept of visual analog scale (VAS), which con-
sisted of a 10 cm line with 0 corresponding to “no pain at 
all” or “not sedated at all” and 10 to “the worst possible 
pain” or “most sedated” was introduced before the study. 
Patients stayed in rest condition in a quiet, temperature- 
and humidity-controlled room. The study was carried out 
in the Pain Clinic, in the mornings, with the patient sited in 
a comfortable long-chair, and the median cephalic or the 
median basilic vein of the arm was heparinized for blood 
collection. Although patients complained of daily pain at 
rest and moving conditions, pain was assessed only during 
resting state, according to the study protocol.
Each T drug was applied in each arm, in a clean area, 
and every patient had applied two of the T preparations, 
one in the right arm and the other in the left arm, in the 
right and left deltoid muscles. The effects of T ketamine 
(1 mg/h), T clonidine (25 μg/h) or T fentanyl (25 μg/h), 
combined with T placebo (CloG, KetG and FenG); or the 
combination of T ketamine and clonidine (Ket-CloG), T 
fentanyl and ketamine (Fen-KetG), or T fentanyl and clo-
nidine (Fen-CloG) were evaluated (Table 1). One anesthe-
siologist blind to the treatments applied the T drugs. The 
placebo and the T systems were individually prepared and 
tested for the pharmacokinetic profile by the Industrial 
Laboratory of the Faculty of Pharmaceutical Sciences of 
Ribeirão Preto, Universidade de São Paulo, and contained 
the same vehicle and similar physical and chemical prop-
erties. The dosages chosen for the different T drugs were 
based on previous experiences with T ketamine5 and T clo-
nidine6 and on published data regarding T fentanyl7. The 
T ketamine cream was developed and tested for control-
led delivery of approximately 1 mg/h ketamine during the 
study period5. Thirty minutes after the T ketamine appli-
cation, detectable levels of plasmatic ketamine were ob-
served. By three and six hours, plasma levels of letamine 
were near 0.05 and 0.08 μg/mL, respectively. The T cloni-
dine system was developed to deliver 25 μg/h of the active 
drug. The process to describe the ideal dose of T clonidine 
was carried out in our Pain Clinic. Different IV doses were 
initially evaluated in patients suffering from chronic pain, 
and the minor dose that resulted in reduced pain scores 
was IV 30 μg every three hours. Subsequent studies con-
ducted by our group determined that 40% of the total clo-
nidine dose from the cream preparation was available as 
plasma free drug. It means that in three hours, although 75 
μg of clonidine was disposable through T application, only 
30 μg of clonidine (correspondent to 40% of 75 μg) was 
available in the plasma, and near 60 μg in six-hour evalua-
tion. Related to the T fentanyl cream, it was developed and 
tested for controlled delivery of 25 μg/h and, after 3 and 6 
hours, its plasma concentration was respectively 0.21 ng/
mL and 0.54 ng/mL.
Pain was evaluated by VAS pain scores (0-10 cm) and by 
plasma noradrenalin measurement prior (time 0-h), 3 hours 
after (time 3-h) and 6 hours after (time 6-h) the T drugs ap-
plication. Plasma measurements of noradrenaline were done 
through High Performance Liquid Chromatography (HPLC) 
at the Faculty of Pharmaceutical Sciences of Ribeirão Preto, 
Universidade de São Paulo. After withdraw of 10-mL blood 
in order to avoid any dilution at the site of collection, 5-ml of 
venous blood was collected at the times: 1) 0-h (just prior to 
the T systems application), 2) 3-h and 3) 6-h after T creams 
application. The samples were transposed in heparinized 
tubes and plasma separated by centrifugation. The plasma 
samples were stored at -70oC until drug assay by HPLC. 
Sedation was evaluated by VAS (0-10 cm) scores at the 
times 0-h, 3-h and 6-h. Mean blood pressure, pulse rate and 
respiratory frequency were evaluated at 30-minute interval. 
Pulse oximetry was continuously evaluated, and additional 
oxygen was available if O
2
 saturation was inferior to 90%. A 
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decrease in mean arterial pressure superior to 15% below in-
itial baseline was treated by incremental doses of ephedrine, 
5 mg IV. Decreases in heart rate below 50 bpm were treated 
with incremental doses of atropine, 0.5 mg IV. The number 
of patients having nausea (of any degree) or vomiting at 
any point was reported. Nausea greater than 4/10 cm at any 
time or vomiting during the study were treated initially with 
metoclopramide 10 mg IV followed by ondansetron 4 mg 
IV, if necessary. Hallucination was treated with incremental 
IV midazolam. Any other adverse events were noted and 
treated, if necessary. At the end of the 6-h evaluation, IV 100 
mg ketoprofen was available at patient request.
Statistical analysis
The number of subjects was based on preliminary experi-
mental data. For this pilot study, we hypothesized that T 
administration of two drugs combination would enhance 
by 100% the analgesic effect of the drug alone, in order 
to get the best combination among the different drugs. If 
we would have estimated a standard deviation for this pro-
spective power analysis an 80% and an α value of 0.05, 
these assumptions would have required at least 6 patients 
in each group to achieve a 100% decrease in VAS scores.
The normality of the distributions was assessed us-
ing the Shapiro-Wilking’s test. Groups were compared 
for demographic data (age, weight, height) and duration 
of chronic pain by ANOVA. Incidence of adverse events, 
gender, ASA status and adjuvant drug used were compared 
between groups by χ2 testcorrected for multiple com-
parisons. Blood pressure, heart rate, respiratory rate and 
VAS scores were compared between groups by two-way 
ANOVA for repeated measures. Tukey analysis was ap-
plied to decrease the probability of type I error. The plasma 
values of noradrenalin and the number of rescue analge-
sics were compared by means of Kruskal-Wallis test, fol-
lowed by the Newman-Keuls test, while data within the 
same group were compared by Friedman test followed 
by the Wilcoxon rank sum test. The value of p<0.05 was 
considered significant. Data are expressed as mean±SD, 
otherwise stated.
RESULTS
Fifty-one patients completed the study protocol. One pa-
tient from the FenG and one from the Fen-CloG were ex-
cluded due to incomplete collected data. A second patient 
from the Fen-CloG gave up his participation in the middle 
of the study, for he was in a hurry to get the bus. The six 
groups showed no differences regarding ASA status, gen-
der, age, weight, height and length in time of pain com-
plaint (p>0.05, Table 2). There were no differences con-
cerning mean blood pressure, pulse rate and respiratory 
frequency measured at 30-min interval among and within 
groups (p>0.05). Pulse oximetry was always maintained 
above 92% and no patients needed supplemental O
2
 during 
the study period.
The data with reference to the pain VAS scores is de-
scribed in Table 3. The analysis within groups revealed 
that the VAS pain score at 6-h was smaller compared to 
the 0-h to the FenG, CloG, KetG and Ket-CloG (p<0.02). 
The groups receiving T fentanyl combined with either 
T ketamine or T clonidine (Fen-KetG and Fen-CloG) 
showed a significantly higher improvement between 0-h 
and 6-h (p<0.01). The comparison among groups re-
vealed that all groups were similar at 0-h and 3-h. At 6-h, 
both Fen-CloG and Fen-KetG had smaller VAS scores 
compared to the administration of the correspondent T 
drug alone (p<0.05, Table 3).
The plasma noradrenaline data is described in Table 
4. The statistical analysis showed that administration of 
T fentanyl alone (FenG) resulted in plasma noradrenaline 
decrease at 6-h compared to itself at 0-h and 3-h (p<0.01), 
while the association of T fentanyl with T clonidine result-
ed in plasma noradrenaline decrease at 3- and 6-h, com-
pared to itself at 0-h and compared to other groups at 3-h 
and 6-h (p<0.01). The combination of both T ketamine and 
clonidine (Ket-CloG) did not result in a better analgesic 
profile (p>0.05).
All groups, except the Ket-CloG, were similar re-
garding adverse effects (p>0.05). One patient from the 
CloG was sedated (VAS 4-cm), and other complained of 
heating, sweating, headache and blurred vision at 6-h. 
The T drugs were cleaned from the skin and the patients 
kept in observation for two extra hours. An IV access 
was obtained and 500 mL lactate solution was infused 
during this period. No other pharmacological treatment 
was necessary and, by the time of discharge, the symp-
toms had ceased. In the KetG, one patient complained 
of nausea (VAS 5-cm) at 4-h and was medicated with 10 
ASA
(II/III)
Gender
(M/F)
Weight
(kg)*
Age
(years)*
Height
(cm)*
Duration of pain 
complaint (years)
CloG 6/3 2/7 72±17 47±13 162±6 7±2
KetG 5/4 2/7 65±11 48±14 160±7 8±4
FenG 5/3 2/6 63±14 51±18 157±9 7±3
Ket-CloG 6/2 2/6 72±14 41±14 162±10 7±3
Fen-KetG 6/3 3/6 68±14 42±13 167±6 8±2
Fen-CloG 4/3 3/4 68±13 46±7 163±6 7±2
TABLE 2 - Demographic data
p>0.05; Clo: clonidine; Ket: ketamine; Fen: fentanyl; G: group.
*Data expressed as mean±SD.
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mg IV metoclopramide. In the FenG, no adverse effects 
were observed during the study period. Two patients 
from the Ket-FenG were mildly sedated at 6-h (VAS 
2-cm). One patient from the Fen-CloG complained of 
transitory nausea (VAS 3-cm) at 4-h, but no pharmaco-
logical treatment was necessary. No other adverse ef-
fects were noted.
The group Ket-Clo was statistically different con-
cerning the sedation (p<0.02). Seven among nine patients 
were sedated by 6-h (VAS 5-8 cm), although respiratory 
frequency and pulse oximetry did not differ within and 
among groups. One of the patients complained about 
headache at 3-h, hence 100 mg IV ketoprofen was infused 
over 20-min. Another patient had hypertension (150/95 
mmHg) at 6-h, and the T drugs were cleaned from the 
skin of both arms. The patient was kept in close observa-
tion and blood pressure measured at 5-min interval for an 
extra 45-min, when blood pressure was 138/83 mmHg. 
She had no clinical discomfort during this period. There 
were no complaints of hallucination or other adverse ef-
fects from patients.
DISCUSSION
The results of the actual study demonstrated that any 
T drug alone resulted in clinical analgesia based on the 
smaller pain VAS scored at 6-h, and that combination of T 
fentanyl with either T ketamine or T clonidine resulted in 
even smaller pain VAS scores at 6-h in comparison to the 
administration of the correspondent T drug alone. The an-
algesia following T fentanyl, in accordance to other stud-
ies7, was further corroborated by decrease of plasma no-
radrenaline levels, when applied alone or combined with 
T clonidin.
The literature reveals that opioids are commonly pre-
scribed for chronic back pain and may be efficacious for 
short-term pain relief, as long-term efficacy for up to 16 
weeks is unclear. In addition, substance use disorders are 
common in patients who take opioids for back pain, and ab-
errant medication-taking behaviors occurred in up to 24% 
of the cases8. Among opioids, T fentanyl was described as 
superior to oral morphine for chronic low back pain. Al-
though daily analgesia was similar between the two opi-
oids, T fentanyl resulted in less constipation and greater 
pain relief at night9. The drugs of the study were chosen 
based on actual data regarding pain processes. Inotropic 
NMDA receptors play a crucial role at pain pathways, and 
their modulation may have potential for therapeutic util-
ity in categories of persistent pain, including neuropathic, 
inflammatory or joint-related pain1 that may contribute to 
low back pain. Ketamine would act by antagonizing the 
NMDA receptor and expression patterns in nociceptive 
pathways1. The second drug studied, the �2-agonist cloni-
dine, was described to exert analgesia by depressing the 
synaptic plasticity in spinal dorsal horn, via activation of 
muscarinic receptor-NO-cGMP pathway2 and, finally, the 
participation of opioids in central plasticity is well know10. 
However, although clinical evaluation revealed to 
some extent benefit of all T drugs tested, the laborato-
rial data revealed that administration of T fentanyl alone 
(FenG) resulted in plasma noradrenaline decrease at 6-h 
compared to itself at the 0-h. Although the minimum effec-
tive concentration of T fentanyl in serum (0.63 ng/mL) was 
achieved at 11.3 ± 4.9 hours after application11, fentanyl 
as a cream preparation took less than six hours, and was 
indirectly supported by the decreased plasma noradrena-
line serum levels. In addition, the association of T fentanyl 
with clonidine resulted in plasma noradrenaline decrease 
even at 3- and 6-h, compared to either drug alone or to the 
other groups, corroborating to the clinical data. It has been 
demonstrated that stress-produced hormones (such as nor-
adrenaline) in the blood serum served as indirect criteria 
of the functional activity of the endogenic antinociceptive 
structures before and after the treatment4. It is a fact that 
interaction of adrenoreceptors with �-opioids is clear in in-
flammation, and that endogenous �(2)-adrenergic systems 
play an important role in the modulation of the effective-
ness of opioids during inflammation process12, what could 
explain the actual results. However, patients who received 
Data expressed as mean±STD. 
Clo: clonidine; Ket: ketamine; Fen: fentanyl; G: group
Comparison within groups: *p<0.02: 0-h compared to 6-h; **p<0.01: 0-h 
compared to 6-h
Comparison among groups; all groups were similar at 0-h and 3-h; +p<0.05: 
Fen-KetG and Fen-CloG- 6-h compared to CloG, KetG and FenG.
0-hour 3-hour 6-hour
CloG 8.6±1.4 6.6±2.7 5.2±2.9*
KetG 8±1 6.1±1.3 5.1±0.7*
FenG 8±1.6 7±2.5 5.4±2.5*
Ket-CloG 7.7±2 6.6±2.3 4.9±2.7*
Fen-Ket 7.8±2.2 5.7±2.8 3.7±3.2**+
Fen-Clo 8.1±1.7 5.7±2.1 3.2±2.5**+
TABLE 3 - Visual analogue pain scores (VAS) 
0-10 cm at the study times 
Data expressed as mean±SD. 
Clo: clonidine; Ket: ketamine; Fen: fentanyl; G: group.
Comparison within groups: *p<0.01; FenG: 6-h compared to 0-h and 3-h; 
Fen-CloG: 3-h compared to 0-h and 6-h compared to 0-h;
Comparison among groups; +p<0.01: Fen-CloG at both 3-h and 6-h, 
compared to the other groups at 3-h and 6-h.
0-hour 3-hour 6-hour
CloG 2.3±0.4 2.4±0.4 2.4±0.4
KetG 2.3±0.5 2.2±0.3 2.6±0.5
FenG 2.5±0.4 2.4±0.5 1.7±0.2*
Ket-CloG 2.4±0.4 2.3±0.4 2.2±0.4
Fen-KetG 2.4±0.5 2.3±0.5 2.6±0.5 
Fen-CloG 2.4±0.3 1.6±0.2*+ 1.5±0.2*+
TABLE 4 - Plasmatic concentration of 
noradrenaline (picogram X 102/mL) at the 
study times 
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only T clonidine (CloG) did not show any decrease in 
plasma noradrenaline levels. Although α2-adrenergic re-
ceptor activation with clonidine in rats experiencing hy-
peralgesia inhibited noradrenaline release13, and clonidine 
resulted in dose-dependent noradrenaline decrease14, by 
6-h evaluation the dose used resulted in no evident de-
crease of noradrenaline by itself. However, the same dose 
further enhanced nordrenaline decrease after T fentanyl at 
3-h evaluation.
In the present study, the combined administration of 
the opioid fentanyl and ketamine resulted in analgesia 
by 6-h, which was evidenced by lower VAS pain scores 
compared to T application of one of the study’ drugs 
alone. In accordance, metabotropic glutamate receptors 
and morphine demonstrated to possess synergistic drug 
interaction for antinociception during phase 2 in the for-
malin test in rats15. The application of T ketamine alone 
(KetG) was analgesic by itself, in accordance to others16, 
and result in greater plasma noradrenaline levels, but ap-
parently blunted the decrease in the Fen-KetG at 6-h. The 
absence of any decrease in plasma noradrenaline level 
was probably secondary to ketamine. Ketamine induces 
sympathomimetic action by impairment of both exocy-
tosis and noradenaline uptake17, plasma noradrenaline 
increased by 20% after bolus IV injection of ketamine 
in volunteers18 and, in dogs, while ketamine used alone 
caused increased noradrenaline concentration, the as-
sociation of the α2-agonist medetomidine prevented or 
blunted this change19. By the time, cortisol levels were 
not measured, as patients received cumulative depot-
dexamethasone, which may have compromised the hy-
pothalamic-pituitary axis. Besides, plasma cortisol serum 
concentration was described as similar regarding healthy 
control and chronic low back pain20,21. 
Interestingly, the combination of both T ketamine and 
clonidine (Ket-CloG) did not result in a better analgesic 
profile compared to the correspondent drug alone and result-
ed in excessive sedation during the 6-h evaluation. The data 
demonstrated that the combined administration of ketamine 
and clonidine did not enhance analgesia, but enhanced ad-
verse effects, which was disappointing to us. The rate of 
opioid prescription in our practice for chronic noncancerous 
pain is less than 5%, as we are among the Pain Specialists 
that do not approve opioids as first-line therapy in nonma-
lignant chronic pain, and there was some degree of expecta-
tive regarding the combination of ketamine and clonidine 
as the “best association” for this purpose. This pilot study 
was indeed conducted and limited to duration of assessment 
of 6 hours because of our interest in defining the best drugs 
association in order to direct us for future and long-time 
evaluation studies, and our greatest expectation was indeed 
the among non-opioid drugs ketamine and clonidine. In the 
mouse hot plate-test, the potency of clonidine was found to 
increase with co-administration of ketamine, but not dextro-
methorphan22. Although this association was controversial 
in acute pain23-25, the continuous intrathecal administration 
of S(+)-ketamine with clonidine resulted in adequate pain 
relief in a patient suffering from intractable neuropathic 
cancer pain26. In the current study, a pure placebo group was 
not included, what could theoretically affect the decrease 
in the VAS scores clinically obtained, but could not have 
blunted the noradrenaline serum data found.
In conclusion, all studied drugs resulted in clinical 
analgesia (VAS) at 6-h, and the association of fentanyl 
with either clonidine or ketamine resulted in even smaller 
VAS scores in comparison to the drugs alone. However, 
T fentanyl analgesia was corroborated by lower plasma 
noradrenaline levels at 6-h when applied alone, or at 3-h 
when combined with T clonidine in patients suffering from 
chronic low back pain. Whether the mechanism of action 
is central, peripheral, or both, is something that could not 
be determined based on these data.
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